President Trump has proposed a one hundred percent tariff on branded and patented pharmaceutical imports. While these were due to take effect by October 2025, companies are still in negotiations and might be eligible for an limited exemption from the tariff if they shift manufacturing to the US or agree to reduce the prices of certain products. The measure is part of a wider plan to rebuild domestic manufacturing and reduce the US trade deficit.